Holders — by stockHoldings — by fund
Spruce Street Capital LP
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 0002050194
$509.7M
disclosed book value
30
positions
11.5%
largest position share
Positions, as of 2026-06-30
top 30 of 30 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | KINIKSA PHARMACEUTICALS INTL | 918,070 | $58.7M | 11.5% |
| 2 | RLAYRELAY THERAPEUTICS INC | 3.0M | $55.8M | 11% |
| 3 | LBRXLB PHARMACEUTICALS INC | 1.4M | $44.7M | 8.8% |
| 4 | RLMDRELMADA THERAPEUTICS INC | 6.4M | $44.2M | 8.7% |
| 5 | ANROALTO NEUROSCIENCE INC | 1.4M | $35.7M | 7% |
| 6 | DNTHDIANTHUS THERAPEUTICS INC | 354,816 | $34.6M | 6.8% |
| 7 | ALKERMES PLC | 543,876 | $28.5M | 5.6% |
| 8 | SVRASAVARA INC | 3.5M | $21.3M | 4.2% |
| 9 | PCVXVAXCYTE INC | 306,047 | $17.8M | 3.5% |
| 10 | ELVNENLIVEN THERAPEUTICS INC | 329,006 | $16.7M | 3.3% |
| 11 | ENTAENANTA PHARMACEUTICALS INC | 1.1M | $15.9M | 3.1% |
| 12 | CATXPERSPECTIVE THERAPEUTICS INC | 3.7M | $12.6M | 2.5% |
| 13 | INFLARX NV | 5.4M | $12.0M | 2.4% |
| 14 | SRZNSURROZEN INC | 432,040 | $11.2M | 2.2% |
| 15 | ALMSALUMIS INC | 392,574 | $11.0M | 2.2% |
| 16 | IPSCCENTURY THERAPEUTICS INC | 4.1M | $9.9M | 2% |
| 17 | NERVMINERVA NEUROSCIENCES INC | 1.7M | $9.2M | 1.8% |
| 18 | SABSSAB BIOTHERAPEUTICS INC | 2.2M | $8.6M | 1.7% |
| 19 | ANTXAN2 THERAPEUTICS INC | 1.7M | $8.0M | 1.6% |
| 20 | ERASERASCA INC | 422,543 | $7.7M | 1.5% |
| 21 | IKTINHIBIKASE THERAPEUTICS INC | 3.6M | $7.3M | 1.4% |
| 22 | RESEARCH ALLIANCE CORP III | 500,000 | $5.3M | 1% |
| 23 | HELIX ACQUISITION CORP III | 500,000 | $5.3M | 1% |
| 24 | ZLABZAI LAB LTD | 279,110 | $5.3M | 1% |
| 25 | ACHVACHIEVE LIFE SCIENCE INC | 736,637 | $4.8M | 0.9% |
| 26 | LXEOLEXEO THERAPEUTICS INC | 928,593 | $4.3M | 0.8% |
| 27 | ALECALECTOR INC | 2.1M | $4.2M | 0.8% |
| 28 | LONALEONABIO INC | 393,701 | $3.6M | 0.7% |
| 29 | CRVSCORVUS PHARMACEUTICALS INC | 231,585 | $3.5M | 0.7% |
| 30 | JATT II ACQUISITION CORP | 160,000 | $1.8M | 0.4% |
Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.